elexacaftor-tezacaftor-ivacaftor Trikafta
Selected indexed studies
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (Lancet Respir Med, 2025) [PMID:39756424]
- Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. (Children (Basel), 2023) [PMID:36980112]
- ** (, 2023) [PMID:38301053]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (2025) pubmed
- Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. (2023) pubmed
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation. (2025) pubmed
- Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. (2025) pubmed
- The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. (2024) pubmed
- PMID:38301053 (2023) pubmed
- PMID:39693469 (2024) pubmed
- PMID:38723138 (2022) pubmed
- Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis. (2020) pubmed
- PMID:38588349 (2024) pubmed